TABLE 1.

Results of i.v. itraconazole treatment in guinea pigs with disseminated fungal infections

Fungus infection	Itraconazole treatment (mg/kg b.i.d.)	First day of treatment	Last day of treatment	Day on which expt ended	n	MSTa ± SD (days)	Organs sampledb	% Organs with no detectable fungus (90% CI)c
A. fumigatus	Placebo	0	13	14	9e	5.8 ± 1.9	K, L, S	3.7 (2.3–9.7)
A. fumigatus	1.25	0	13	14	6	7.8 ± 4.2	K, L, S	38.9 (20.0–57.8)
A. fumigatus	2.5	0	13	14	6	7.0 ± 2.4	K, L, S	55.6 (36.3–74.8)
A. fumigatus	5	0	13	14	6	11.0 ± 3.7*	K, L, S	88.9 (76.7–100)
A. fumigatus	5d	0	13	14	6	9.8 ± 3.9*	K, L, S	72.2 (54.9–89.6)
C. albicans	Placebo	0	9	10	11e	4.9 ± 1.4	B, K, L, S, Sk	1.8 (1.1–4.8)
C. albicans	1.25	0	9	10	6	5.5 ± 2.4	B, K, L, S, Sk	33.3 (19.2–47.5)
C. albicans	2.5	0	9	10	6	8.8 ± 2.9*	B, K, L, S, Sk	80.0 (68.0–92.0)
C. albicans	2.5	1	13	17	5	17 ± 0.0*	B, K, L, S, Sk	100.0
C. albicans	5	1	13	17	6	17 ± 0.0*	B, K, L, S, Sk	100.0
C. albicans	2.5	3	13	17	6	9.7 ± 6.0	B, K, L, S, Sk	40.0 (25.3–54.7)
C. neoformans	Placebo	0	9	10	3	NA	B, Ly, M, Sk	33.3 (10.9–55.7)
C. neoformans	2.5	0	9	10	6	NA	B, Ly, M, Sk	95.8 (89.1–100)
C. neoformans	5	0	9	10	5	NA	B, Ly, M, Sk	100.0
C. neoformans	Placebo	0	29	30	3	NA	B, Ly, M, Sk	25.0 (10.5–39.5)
C. neoformans	2.5	0	29	30	4	NA	B, Ly, M, Sk	100.0
C. neoformans	5	0	29	30	5	NA	B, Ly, M, Sk	100.0
C. neoformans	2.5	10	29	30	6	NA	B, Ly, M, Sk	20.8 (7.2–34.5)
C. neoformans	5	10	29	30	8e	NA	B, Ly, M, Sk	62.5 (48.4–76.6)

^aMST, mean survival time. Asterisks indicate significant prolongation of survival over that of the placebo-treated group (Mann-Whitney U test, P < 0.05). NA, not applicable; no fatalities. 

^bB, brain; K, left kidney; L, liver; Ly, lymph; M, muscle; S, spleen; Sk, skin. 

^cCI, confidence interval. 

^dAnimals immunosuppressed by pretreatment with mechlorethamine hydrochloride. 

^eData pooled from two experiments.